Pfizer Closes $10 Billion Deal for Metsera, Wins Fierce Bidding War Against Rival Novo Nordisk
Pfizer has secured a major victory in the race for new weight-loss drugs. The U.S. drugmaker won a fierce bidding war against its rival, Denmark’s Novo Nordisk. Pfizer confirmed a deal to acquire the obesity drug developer, Metsera. The final value could reach over $10 billion. Novo Nordisk’s bid was initially called superior. However, Pfizer…